Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.
- Published In:
- European journal of heart failure, 27(3), 540-551 (2025)
- Authors:
- Neves, João Sérgio, Leite, Ana Rita, Mentz, Robert J(7), Holman, Rury R, Zannad, Faiez, Butler, Javed, Packer, Milton, Ferreira, João Pedro
- Database ID:
- RPEP-12761
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-12761APA
Neves, João Sérgio; Leite, Ana Rita; Mentz, Robert J; Holman, Rury R; Zannad, Faiez; Butler, Javed; Packer, Milton; Ferreira, João Pedro. (2025). Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.. European journal of heart failure, 27(3), 540-551. https://doi.org/10.1002/ejhf.3478
MLA
Neves, João Sérgio, et al. "Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.." European journal of heart failure, 2025. https://doi.org/10.1002/ejhf.3478
RethinkPeptides
RethinkPeptides Research Database. "Cardiovascular outcomes with exenatide in type 2 diabetes ac..." RPEP-12761. Retrieved from https://rethinkpeptides.com/research/neves-2025-cardiovascular-outcomes-with-exenatide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.